BACKGROUND: Survivin, a novel member of the inhibitor of apoptosis family, plays an important role in cell cycle regulation. A common polymorphism at the survivin gene promoter (G/C at position 31) was shown to be correlated with survivin gene expression in cancer cell lines. AIM: To investigate whether this polymorphism could be involved in the development of human papillomavirus (HPV)-associated cervical carcinoma. METHODS: Survivin promoter polymorphism was detected in patients with cervical cancer, in patients with equivocal cytological atypia and in a control population using polymerase chain reaction (PCR-restriction fragment length polymorphism (RFLP) and PCR-single strand conformation polymorphism analysis. HPV was typed in patients with cervical cancer and cytological atypia using PCR-RFLP. RESULTS: No statistically significant differences were found in the genotype distributions of the survivin promoter variants among our study groups. CONCLUSIONS: The survivin promoter polymorphism at position 31 may not represent an increased risk for the development of cervical cancer, at least in the population studied here.
BACKGROUND: Survivin, a novel member of the inhibitor of apoptosis family, plays an important role in cell cycle regulation. A common polymorphism at the survivin gene promoter (G/C at position 31) was shown to be correlated with survivin gene expression in cancer cell lines. AIM: To investigate whether this polymorphism could be involved in the development of human papillomavirus (HPV)-associated cervical carcinoma. METHODS: Survivin promoter polymorphism was detected in patients with cervical cancer, in patients with equivocal cytological atypia and in a control population using polymerase chain reaction (PCR-restriction fragment length polymorphism (RFLP) and PCR-single strand conformation polymorphism analysis. HPV was typed in patients with cervical cancer and cytological atypia using PCR-RFLP. RESULTS: No statistically significant differences were found in the genotype distributions of the survivin promoter variants among our study groups. CONCLUSIONS: The survivin promoter polymorphism at position 31 may not represent an increased risk for the development of cervical cancer, at least in the population studied here.
Authors: Agnes A Borbély; Melinda Murvai; József Kónya; Zoltán Beck; Lajos Gergely; Fengzhi Li; György Veress Journal: J Gen Virol Date: 2006-02 Impact factor: 3.891
Authors: A Islam; H Kageyama; N Takada; T Kawamoto; H Takayasu; E Isogai; M Ohira; K Hashizume; H Kobayashi; Y Kaneko; A Nakagawara Journal: Oncogene Date: 2000-02-03 Impact factor: 9.867
Authors: Salvatore de Maria; Lorenzo Lo Muzio; Alessandra Braca; Paolo Rega; Amalia Cassano; Angela Vinella; Ruggiero Fumarulo; Rosario Serpico; Ernesto Farina; Vittoria Metafora; Giuseppe Pannone; Gian Pietro Ravagnan; Salvatore Metafora; Corrado Rubini; Maria Carteni; Maria Addolorata Mariggiò Journal: Oncol Lett Date: 2011-07-05 Impact factor: 2.967
Authors: Xiaoya Yang; Gang Xiong; Xuedan Chen; Xueqing Xu; Kai Wang; Yong Fu; Kang Yang; Yun Bai Journal: J Cancer Res Clin Oncol Date: 2009-04-08 Impact factor: 4.553